TMDX: financial statements from SEC — TradeAlmanac

TMDX

TransMedics Group, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	174m	144m	157m	144m	109m	114m
Cost of revenue	73m	59m	61m	55m	48m	45m
Gross profit	101m	85m	97m	88m	61m	69m
Research and development	25m	15m	16m	17m	14m	14m
Selling, general and administrative	63m	46m	44m	44m	43m	43m
Operating expenses	88m	61m	60m	61m	57m	57m
Operating income	13m	23m	37m	27m	4m	13m
Interest expense	—	—	—	—	—	4m
Pre-tax income	8m	23m	36m	27m	4m	12m
Income tax	1m	−1m	1m	994,000	29,000	−41,000
Net income	7m	24m	35m	26m	4m	12m
Earnings per share	0.21	0.71	1.03	0.76	0.13	0.37
Earnings per share, diluted	0.20	0.66	0.92	0.70	0.12	0.35
Weighted average shares	34m	34m	34m	34m	33m	33m
Weighted average shares, diluted	36m	41m	41m	40m	36m	35m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	480m	489m	467m	401m	311m	337m	331m	363m
Receivables	91m	84m	81m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	25m	−3m
Depreciation and amortisation	12m	6m
Share-based compensation	10m	9m
Capital expenditure	37m	27m
Investing cash flow	−37m	−27m
Financing cash flow	4m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)